IMMUCELL CORP /DE/ (ICCC): Results of Operations and Financial Condition
IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops,
How this was made
The 30-second read
Why it matters
The filing is a primary earnings-style disclosure with specific financial metrics and a capital plan to expand freeze-drying and First Defense processing capacity, intended to improve supply reliability and long-term economics.
Market read
Traders can update valuation and near-term expectations using the reported Q2 revenue, net income, gross margin decline, cash increase, and the stated plan to triple capacity over the next 18 months.
What to watch
The $2M settlement payment boosted net income and adjusted EBITDA; traders may normalize earnings and focus on whether margin improves as manufacturing process changes and capacity expansion take effect.
Background
The company filed an SEC 8-K with Exhibit 99.1 announcing unaudited Q2 2026 financial results and discussing drivers like distributor volume growth and manufacturing headwinds.
Ticker impact
ImmuCell reported Q2 2026 results, including net income of $1.8M, revenue up 11.5% to $7.2M, and a $2M settlement benefit.
Near-term bias modestly positive on revenue and EBITDA strength, tempered by margin compression and reliance on one-time settlement.
The filing provides concrete quarterly datapoints (revenue, net income, gross margin, cash) plus a forward-looking capacity expansion plan expected to triple capacity over 18 months.
Market effects
Animal health biologics names may see read-through interest in manufacturing capacity and margin trajectory, but this is company-specific.
Limited, as the disclosure is for a small-cap US-listed issuer with no stated regional policy or demand shock.
Low, no international regulatory or supply-chain event beyond the company’s own manufacturing expansion.
Counterpoint
Gross margin deterioration (33.9% vs 43.7% prior year) suggests underlying cost structure may still be deteriorating despite revenue growth.
Key entities
- public_companyImmuCell Corporation
Nasdaq-listed animal health biologics company reporting Q2 2026 results and announcing capacity expansion investments.
- productFirst Defense
Colostrum-based product referenced in the capacity expansion plan for liquid processing capacity.
- programRe-Tain
Discontinued development program whose associated facilities/equipment are referenced for First Defense capacity expansion, and whose former CMO settlement contributed to Q2 income.
